- Home
- NNVC vs NRXS Comparison
NNVC vs NRXS Comparison
Compare NNVC & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNVC
- NRXS
- Stock Information
- Founded
- NNVC 2005
- NRXS 2011
- Country
- NNVC United States
- NRXS United States
- Employees
- NNVC N/A
- NRXS N/A
- Industry
- NNVC Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- NNVC Health Care
- NRXS
- Exchange
- NNVC Nasdaq
- NRXS Nasdaq
- Market Cap
- NNVC 17.7M
- NRXS 20.3M
- IPO Year
- NNVC N/A
- NRXS 2023
- Fundamental
- Price
- NNVC $1.35
- NRXS $3.15
- Analyst Decision
- NNVC Strong Buy
- NRXS
- Analyst Count
- NNVC 1
- NRXS 0
- Target Price
- NNVC $6.50
- NRXS N/A
- AVG Volume (30 Days)
- NNVC 130.2K
- NRXS 24.0K
- Earning Date
- NNVC 11-22-2024
- NRXS 11-12-2024
- Dividend Yield
- NNVC N/A
- NRXS N/A
- EPS Growth
- NNVC N/A
- NRXS N/A
- EPS
- NNVC N/A
- NRXS N/A
- Revenue
- NNVC N/A
- NRXS $2,456,219.00
- Revenue This Year
- NNVC N/A
- NRXS $383.16
- Revenue Next Year
- NNVC N/A
- NRXS N/A
- P/E Ratio
- NNVC N/A
- NRXS N/A
- Revenue Growth
- NNVC N/A
- NRXS N/A
- 52 Week Low
- NNVC $1.00
- NRXS $2.00
- 52 Week High
- NNVC $3.59
- NRXS $3.89
- Technical
- Relative Strength Index (RSI)
- NNVC 42.61
- NRXS 61.15
- Support Level
- NNVC $1.44
- NRXS $2.25
- Resistance Level
- NNVC $1.58
- NRXS $3.19
- Average True Range (ATR)
- NNVC 0.08
- NRXS 0.37
- MACD
- NNVC -0.01
- NRXS 0.06
- Stochastic Oscillator
- NNVC 26.79
- NRXS 94.08
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).